{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:10:35Z","timestamp":1763017835197,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T00:00:00Z","timestamp":1517875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T00:00:00Z","timestamp":1517875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Mabel A. Woodyard Fellowship in Neurodegenerative Disorders"},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2TR000119"],"award-info":[{"award-number":["KL2TR000119"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research in ALS and Related Disorders for Therapeutic Development Consortium Research Fellowship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12874-018-0479-9","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T13:31:59Z","timestamp":1517923919000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression"],"prefix":"10.1186","volume":"18","author":[{"given":"Alex G.","family":"Karanevich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Statland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byron J.","family":"Gajewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianghua","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"issue":"6","key":"479_CR1","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/(SICI)1097-4598(200006)23:6<874::AID-MUS5>3.0.CO;2-U","volume":"23","author":"C Armon","year":"2000","unstructured":"Armon C, Graves MC, Moses D, Forte DK, Sepulveda L, Darby SM, et al. Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. Muscle Nerve. 2000;23(6):874\u201382.","journal-title":"Muscle Nerve"},{"issue":"5","key":"479_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/mus.10090","volume":"25","author":"T Magnus","year":"2002","unstructured":"Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve. 2002;25(5):709\u201314.","journal-title":"Muscle Nerve"},{"issue":"10","key":"479_CR3","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00415-010-5609-1","volume":"257","author":"PH Gordon","year":"2010","unstructured":"Gordon PH, Cheng B, Salachas F, Pradat PF, Bruneteau G, Corcia P, et al. Progression in ALS is not linear but is curvilinear. J Neurol. 2010;257(10):1713\u20137.","journal-title":"J Neurol"},{"issue":"12","key":"479_CR4","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.2169\/internalmedicine.51.7465","volume":"51","author":"K Ikeda","year":"2012","unstructured":"Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med. 2012;51(12):1501\u20138.","journal-title":"Intern Med"},{"issue":"2","key":"479_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1212\/01.wnl.0000194316.91908.8a","volume":"66","author":"F Kimura","year":"2006","unstructured":"Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265\u20137.","journal-title":"Neurology"},{"issue":"1-2","key":"479_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jns.2008.07.016","volume":"275","author":"K Kollewe","year":"2008","unstructured":"Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B. ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci. 2008;275(1-2):69\u201373.","journal-title":"J Neurol Sci"},{"issue":"5-6","key":"479_CR7","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3109\/17482960802320545","volume":"10","author":"DM Pastula","year":"2009","unstructured":"Pastula DM, Coffman CJ, Allen KD, Oddone EZ, Kasarskis EJ, Lindquist JH, et al. Factors associated with survival in the National Registry of veterans with ALS. Amyotroph Lateral Scler. 2009;10(5-6):332\u20138.","journal-title":"Amyotroph Lateral Scler"},{"issue":"2","key":"479_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s13311-015-0336-z","volume":"12","author":"N Zach","year":"2015","unstructured":"Zach N, Ennist DL, Taylor AA, Alon H, Sherman A, Kueffner R, et al. Being PRO-ACTive: what can a clinical trial database reveal about ALS? Neurotherapeutics. 2015;12(2):417\u201323.","journal-title":"Neurotherapeutics"},{"issue":"6","key":"479_CR9","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00415-014-7564-8","volume":"262","author":"H Creemers","year":"2015","unstructured":"Creemers H, Grupstra H, Nollet F, van den Berg LH, Beelen A. Prognostic factors for the course of functional status of patients with ALS: a systematic review. J Neurol. 2015;262(6):1407\u201323.","journal-title":"J Neurol"},{"issue":"12","key":"479_CR10","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1007\/s10072-015-2343-6","volume":"36","author":"J Mandrioli","year":"2015","unstructured":"Mandrioli J, Biguzzi S, Guidi C, Sette E, Terlizzi E, Ravasio A, et al. Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy. Neurol Sci. 2015;36(12):2243\u201352.","journal-title":"Neurol Sci"},{"issue":"3-4","key":"479_CR11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3109\/21678421.2014.990036","volume":"16","author":"H Watanabe","year":"2015","unstructured":"Watanabe H, Atsuta N, Nakamura R, Hirakawa A, Watanabe H, Ito M, et al. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(3-4):230\u20136.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"19","key":"479_CR12","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1212\/WNL.0000000000000951","volume":"83","author":"N Atassi","year":"2014","unstructured":"Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014;83(19):1719\u201325.","journal-title":"Neurology"},{"issue":"11","key":"479_CR13","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1474-4422(14)70129-2","volume":"13","author":"H Mitsumoto","year":"2014","unstructured":"Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13(11):1127\u201338.","journal-title":"Lancet Neurol"},{"doi-asserted-by":"crossref","unstructured":"Zach N, Kueffner R, Atassi N, Chio A, Cudkowicz M, Hardiman O, et al. The ALS Stratification Prize-Using the Power of Big Data and Crowdsourcing for Catalyzing Breakthroughs in Amyotrophic Lateral Sclerosis (ALS) (P5.102). Neurology. 2016;86(16 Supplement).","key":"479_CR14","DOI":"10.1212\/WNL.86.16_supplement.P5.102"},{"key":"479_CR15","volume-title":"Bayesian data analysis. Third edition. Ed","author":"A Gelman","year":"2014","unstructured":"Gelman A. Bayesian data analysis. Third edition. Ed. Boca Raton: CRC Press; 2014."},{"key":"479_CR16","volume-title":"R: a language and environment for statistical computing","author":"R Development Core Team","year":"2016","unstructured":"R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2016."},{"issue":"4","key":"479_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1023\/A:1008929526011","volume":"10","author":"DJ Lunn","year":"2000","unstructured":"Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000;10(4):325\u201337.","journal-title":"Stat Comput"},{"issue":"3","key":"479_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.18637\/jss.v012.i03","volume":"12","author":"S Sturtz","year":"2005","unstructured":"Sturtz S, Ligges U, Gelman A. R2WinBUGS: A Package for Running WinBUGS from R. J Stat Softw. 2005;12(3):16.","journal-title":"J Stat Softw"},{"issue":"1-2","key":"479_CR19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3109\/17482960903093710","volume":"11","author":"C Castrillo-Viguera","year":"2010","unstructured":"Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler. 2010;11(1-2):178\u201380.","journal-title":"Amyotroph Lateral Scler"},{"issue":"1-2","key":"479_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3109\/21678421.2013.838970","volume":"15","author":"R Gomeni","year":"2014","unstructured":"Gomeni R, Fava M. Pooled resource open-access ALSCTC. Amyotrophic lateral sclerosis disease progression model. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(1-2):119\u201329.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"479_CR21","first-page":"115","volume-title":"Shrinkage Estimation in Multilevel Normal Models","author":"CN Morris","year":"2012","unstructured":"Morris CN, Lysy M. Shrinkage Estimation in Multilevel Normal Models; 2012. p. 115\u201334."},{"doi-asserted-by":"crossref","unstructured":"Stein C, editor Inadmissibility of the Usual Estimator for the Mean of a Multivariate Normal Distribution. Proceedings of the Third Berkeley Symposium on Mathematical Statistics and Probability, Volume 1: Contributions to the Theory of Statistics. Berkeley, Calif.: University of California Press. 1956","key":"479_CR22","DOI":"10.1525\/9780520313880-018"},{"issue":"5-6","key":"479_CR23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3109\/21678421.2016.1140786","volume":"17","author":"M Proudfoot","year":"2016","unstructured":"Proudfoot M, Jones A, Talbot K, Al-Chalabi A, Turner MR. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(5-6):414\u201325.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"9","key":"479_CR24","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1001\/jamaneurol.2014.1129","volume":"71","author":"A Chio","year":"2014","unstructured":"Chio A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmozzi F, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol. 2014;71(9):1134\u201342.","journal-title":"JAMA Neurol"},{"issue":"5-6","key":"479_CR25","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3109\/21678421.2014.893361","volume":"15","author":"T Hothorn","year":"2014","unstructured":"Hothorn T, Jung HH. RandomForest4Life: a random Forest for predicting ALS disease progression. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5-6):444\u201352.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"1","key":"479_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nbt.3051","volume":"33","author":"R Kuffner","year":"2015","unstructured":"Kuffner R, Zach N, Norel R, Hawe J, Schoenfeld D, Wang L, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol. 2015;33(1):51\u20137.","journal-title":"Nat Biotechnol"},{"issue":"7-8","key":"479_CR27","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3109\/21678421.2015.1074698","volume":"16","author":"H Shamshiri","year":"2015","unstructured":"Shamshiri H, Fatehi F, Davoudi F, Mir E, Pourmirza B, Abolfazli R, et al. Amyotrophic lateral sclerosis progression: Iran-ALS clinical registry, a multicentre study. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):506\u201311.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"7","key":"479_CR28","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/sim.6403","volume":"34","author":"BJ Gajewski","year":"2015","unstructured":"Gajewski BJ, Berry SM, Quintana M, Pasnoor M, Dimachkie M, Herbelin L, et al. Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot. Stat Med. 2015;34(7):1134\u201349.","journal-title":"Stat Med"},{"issue":"21","key":"479_CR29","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1002\/sim.6957","volume":"35","author":"M Rosenblum","year":"2016","unstructured":"Rosenblum M, Luber B, Thompson RE, Hanley D. Group sequential designs with prospectively planned rules for subpopulation enrichment. Stat Med. 2016;35(21):3776\u201391.","journal-title":"Stat Med"},{"issue":"8","key":"479_CR30","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/sim.6794","volume":"35","author":"G Shan","year":"2016","unstructured":"Shan G, Wilding GE, Hutson AD, Gerstenberger S. Optimal adaptive two-stage designs for early phase II clinical trials. Stat Med. 2016;35(8):1257\u201366.","journal-title":"Stat Med"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-018-0479-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12874-018-0479-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-018-0479-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:29:58Z","timestamp":1719793798000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-018-0479-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,6]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["479"],"URL":"https:\/\/doi.org\/10.1186\/s12874-018-0479-9","relation":{},"ISSN":["1471-2288"],"issn-type":[{"type":"electronic","value":"1471-2288"}],"subject":[],"published":{"date-parts":[[2018,2,6]]},"assertion":[{"value":"14 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In all of the trials that generated the data included in this database, study protocols were approved by the participating medical centers and all participating patients gave informed consent. De-identified data from these trials were donated to the PRO-ACT database for research purposes only and under the explicit conditions that Prize4Life and all users of the data would maintain the anonymity of subjects and not attempt to discover the identity of any subject. In the rare cases where donated data was not already completely anonymized, donated data was further anonymized following the HIPAA de-identification conventions for personal health information: any potential patient initials and\/or dates of birth were removed, new randomized subject numbers were created, and wherever possible, trial-specific information was removed in the merging of datasets, including trial center identity and location, trial dates, or other identifying information. This project was deemed not to constitute human subjects research and the need for ethical approval for this work was waived by the University of Kansas Medical Center\u2019s Human Research Protection Program.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Jeffrey M. Statland is a consultant for aTyr, Acceleron, Fulcrum, Regeneron, and Strongbridge. The remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"19"}}